Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial / 中华内分泌代谢杂志

ABSTRACT

Almost all the type 2 diabetic patients require insulin therapy as disease progresses over time. However, there are still a large number of patients who fail to achieve glycemic target with basal insulin therapy. How to optimize glycemic control in these patients is a problem in clinical practice. Glucagon-like peptide 1 (GLP-1)receptor agonist is a new type of anti-hyperglycemic agent with complementary mechanisms of actions to basal insulin,helpful for improved glycemic control in type 2 diabetic patients with basal insulin treatment. Therefore, clinical evidence in Chinese population is valuable for clinical diabetes management in China. This paper is the translation of "Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulinThe GetGoal-L-C randomized trial",published on"Diabetes,Obesity&Metabolism" in February 2018[Yang W,Min K,Zhou Z,et al. Diabetes,Obesity&Metabolism,2018,20(2)335-343] with open access, which demonstrated efficacy and safety of lixisenatide in a predominantly Asian population with uncontrolled type 2 diabetes as add-on therapy to basal insulin.